Search

everythinglearnresearchcommunity

for

Search:↓

Tofacitinib effectively treated a woman's complex autoimmune and autoinflammatory disorders.

Baricitinib was effective in treating a patient with dermatomyositis and hair loss.

Danoprevir, remdesivir, and saridegib may effectively inhibit SARS-CoV-2.

Upadacitinib effectively treated severe atopic dermatitis, vitiligo, and alopecia areata in one patient.

Tofacitinib significantly improved symptoms in a patient with overlapping autoimmune disorders.

A 50 mg non-loading dose of ritlecitinib is safe for adults and adolescents.

As of December 2021, the most effective COVID-19 treatments were monoclonal antibodies and possibly early-administered convalescent plasma, while several drugs were found ineffective or were still under evaluation.

Infectious virus was not found after the third remdesivir dose, suggesting early end of isolation is possible.

CTP-543 significantly improved eyebrow and eyelash regrowth and patient satisfaction in adults with alopecia areata.

Low-dose tofacitinib is effective and cheaper for severe alopecia areata.

Fluconazole might be a new treatment for a type of diabetes that affects water balance in the body.

JAK inhibitors can be safely used in alopecia areata patients with latent hepatitis B or tuberculosis, with proper monitoring.

Baricitinib was effective in regrowing hair in patients with different levels of alopecia areata severity.

The anti-viral drug Elvitegravir may protect brain cells from damage related to neurodegenerative diseases.

Baricitinib effectively treats alopecia areata, with over half of patients improving after 52 weeks.

Bendamustine combined with tucidinostat may effectively treat adult T-cell leukemia.

A 50 mg daily dose of ritlecitinib is effective for alopecia areata, with temporary treatment breaks up to 6 weeks not affecting results.

A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.

50-mg ritlecitinib capsules are bioequivalent to 100-mg capsules.

Deuruxolitinib effectively regrows hair in adults with alopecia areata and is well tolerated.

Interferon α‐2b can temporarily reduce hepatitis C virus and normalize liver enzyme levels.

Baricitinib is effective and safe for treating localized vitiligo, alone or with topical tacrolimus.

JAK inhibitors are effective and generally safe for treating alopecia areata, but monitoring for side effects is important.

Baricitinib may cause low blood sugar in some patients, so careful monitoring is needed.

Baricitinib is effective for severe alopecia areata with manageable side effects, mainly upper respiratory infections.

Ritlecitinib effectively reduces hair loss in JAK inhibitor-naïve alopecia areata patients.

JAK inhibitors can be safely used for alopecia areata in patients with latent hepatitis B or stable tuberculosis with proper monitoring.

Switching between the medications tofacitinib and baricitinib can be effective for treating hair loss in alopecia areata.

Tofacitinib and adalimumab are promising treatments for cicatricial alopecia with few side effects.